ptla

ptla is the NASDAQ ticker that formerly represented Portola Pharmaceuticals, a United States-based biopharmaceutical company focused on therapies for acute cardiovascular events and bleeding management. The company pursued programs related to anticoagulation reversal and other cardiovascular interventions, with an emphasis on addressing life-threatening or uncontrolled bleeding associated with anticoagulant use.

Portola’s lead product was andexanet alfa, a reversal agent designed to counteract the effects of factor Xa inhibitors used in anticoagulation therapy. The development and potential clinical use of this reversal agent were central to Portola’s strategy, alongside research programs aimed at complementing anticoagulant therapies and bleeding management.

In 2019, Portola Pharmaceuticals was acquired by Alexion Pharmaceuticals, and Portola operated as part of Alexion thereafter. The integration led to the delisting of PTLA and the dissolution of Portola as an independent company. In 2020, AstraZeneca completed its acquisition of Alexion, bringing Portola’s assets under AstraZeneca’s corporate umbrella through the acquisition chain.

Today, PTLA is no longer an active trading ticker, and Portola Pharmaceuticals exists as a historical entity within the broader context of the companies that acquired it. The Portola storyline is primarily remembered for its focus on anticoagulation reversal therapies and its transition through major pharmaceutical industry consolidations.